Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Sidney Smith

MOHS-Micrographic Surgery Savannah, GA Medical Doctor

NPI 1104817410 CMS profile 321811

900 Mohawk St, Savannah, GA 31419

Open in the dashboard

General payments

$9,181

399 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Research they led as principal investigator

$867,404 paid to institutions, not to them · program years 2020–2025

Through program year 2025, Sidney Smith of Savannah, GA is reported in the CMS Open Payments database as having received $9,181 across 399 general payments and $0 in research payments paid to them. Separately, studies naming them as principal investigator received $867,404 in research payments, paid to institutions rather than to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them. The principal-investigator line is research money paid to institutions for studies they led — not to them — and is not added to anything either.

General payments for this record sit in the 85th percentile of MOHS-Micrographic Surgery profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

7 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $1,338 61
2024 General $2,352 77
2023 General $1,070 55
2022 General $1,389 63
2021 General $1,415 61
2020 General $740 34
2019 General $878 48

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Sidney Smith
  • MOHS-Micrographic Surgery median
  • Middle half of MOHS-Micrographic Surgery
  • National median

In program year 2025, general payments to Sidney Smith were reported at $1,338. Among 1,077 MOHS-Micrographic Surgery profiles paid that year, the median was $465 and the middle half received between $145 and $1,066.

Show as a table
Year Sidney Smith MOHS-Micrographic Surgery median Middle half National median
2019 $878 $316 $106–$785 $163
2020 $740 $162 $68–$412 $114
2021 $1,415 $243 $87–$654 $132
2022 $1,389 $300 $102–$887 $149
2023 $1,070 $364 $125–$1,010 $160
2024 $2,352 $445 $142–$1,108 $164
2025 $1,338 $465 $145–$1,066 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. Sun Pharmaceutical Industries Inc. $1,104 52 payments
  2. Pfizer Inc. $1,054 66 payments
  3. ConvaTec Inc. $952 6 payments
  4. Regeneron Healthcare Solutions, Inc. $935 34 payments
  5. AbbVie, Inc. $895 54 payments
  6. Genzyme Corporation $693 27 payments
  7. Incyte Corporation $555 19 payments
  8. Amgen Inc. $502 27 payments
  9. Ortho Dermatologics, a division of Bausch Health US, LLC $398 17 payments
  10. UCB, Inc. $306 8 payments
  11. Other $1,789 89 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Food and Beverage $7,986 390 payments
  2. Education $616 8 payments
  3. Travel and Lodging $579 1 payment
Products named General payments · program years 2019–2025
  1. INNOVAMATRIX AC $952 6 payments
  2. CIBINQO $825 51 payments
  3. ILUMYA $737 44 payments
  4. DUPIXENT Inflammation And Immunology $654 26 payments
  5. DUPIXENT Immunology $577 33 payments
  6. EUCRISA $534 45 payments
  7. OPZELURA $488 18 payments
  8. Otezla $400 21 payments
  9. LITFULO $397 39 payments
  10. LIBTAYO $393 8 payments
  11. Other $4,221 218 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 30 drugs

Part D claims

1,184

Median for Dermatology: 534

Drug cost

$693,761

Median for Dermatology: $67,151

Branded share of claims

14.9%

Median for Dermatology: 8.1%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Dupixent Pen Dupilumab Brand 71 $282,775
Humira(Cf) Pen Adalimumab Brand 13 $177,104
Rinvoq Upadacitinib Brand 14 $85,793
Otezla Apremilast Brand 13 $63,140
Dupixent Syringe Dupilumab Brand 12 $52,913
Fluorouracil Generic 126 $7,791
Clobetasol Propionate Generic 151 $5,608
Triamcinolone Acetonide Generic 182 $3,022
Clindamycin Phosphate Generic 55 $2,467
Pimozide Generic 11 $2,096

The 10 drugs with the highest cost, of 30 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 13,550 Part D prescribers listed as Dermatology; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 98 billing codes

Paid by Medicare

$2,038,953

Of which drugs: $771,763

Medicare patients

2,577

Average age 75

Services billed

12,885

1,232 women, 1,345 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 75%
Arthritis 45%
Diabetes 26%
Ischemic heart disease 24%
Chronic kidney disease 19%
Atrial fibrillation 17%
Cancer 15%
Depression 14%
Drugs given in the clinic that this provider billed Medicare Part B for
Drug given in the clinic Where Patients Services Paid by Medicare
Amnioarmor, per square centimeter Q4188 Office 124 996 $676,674

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Payments and prescribing

First 5 of 20 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
DUPIXENT
  • GENZYME CORPORATION $151
  • Regeneron Healthcare Solutions, Inc. $65
$216 83 —
CIBINQO
  • PFIZER INC. $175
$175 — —
ILUMYA
  • Sun Pharmaceutical Industries Inc. $168
$168 — —
Otezla
  • Amgen Inc. $73
$73 13 —
RINVOQ
  • AbbVie, Inc. $70
$70 14 —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

See all 20 in the dashboard with a free account

Records

399 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other MOHS-Micrographic Surgery in Georgia

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record